Journal
CANCER DISCOVERY
Volume 13, Issue 1, Pages 56-69Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-22-0381
Keywords
-
Categories
Ask authors/readers for more resources
The transcription factor and tumor suppressor protein p53 is frequently mutated and inactivated in cancer. This study successfully identified covalent compounds that selectively react with the p53 somatic mutant cysteine Y220C and restore wild-type thermal stability.
The transcription factor and tumor suppressor protein p53 is the most frequently mutated and inactivated gene in cancer. Mutations in p53 result in deregulated cell proliferation and genomic instability, both hallmarks of cancer. There are currently no therapies avail-able that directly target mutant p53 to rescue wild-type function. In this study, we identify covalent compounds that selectively react with the p53 somatic mutant cysteine Y220C and restore wild-type thermal stability.SIGNIFICANCE: The tumor suppressor p53 is the most mutated gene in cancer, and yet no therapeutics to date directly target the mutated protein to rescue wild-type function. In this study, we identify the first allele-specific compound that selectively reacts with the cysteine p53 Y220C to rescue wild-type thermal stability and gene activation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available